On January 11, 2021 Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, reported that preliminary safety and efficacy data from a trial evaluating the arginase inhibitor INCB001158, which is being developed by Incyte Pharmaceuticals, reported that it will be presented in a virtual poster session at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) 2021 Gastrointestinal Cancers Virtual Symposium taking place January 15-17, 2021 (Press release, Calithera Biosciences, JAN 11, 2021, View Source [SID1234573819]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Presentation details:
Date: Available starting on Friday, January 15 at 5:00 a.m. Pacific Time
Title: A phase I/II study of safety and efficacy of the arginase inhibitor INCB001158 plus chemotherapy in patients with advanced biliary tract cancers
Lead Author: Milind Javle, M.D., University of Texas MD Anderson Cancer Center
Poster Session: Hepatobiliary Cancer, Abstract 311
Additional meeting information and accepted abstracts can be found at the ASCO (Free ASCO Whitepaper) website www.asco.org.